Dramatic response of metaplastic breast cancer to chemo-immunotherapy.

about

In-vitro effect of pembrolizumab on different T regulatory cell subsets.Metaplastic Breast Cancer: Practice Patterns, Outcomes, and the Role of Radiotherapy.

P2860

Q47616276-EB0A1F79-15E7-4B88-884B-4794D0DE0642 Q48265396-C0F6BDC4-6EB3-4A37-B809-72E62135D70B

P2860

Dramatic response of metaplastic breast cancer to chemo-immunotherapy.

Item

http://www.wikidata.org/entity/Q42243444

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Dramatic response of metaplastic breast cancer to chemo-immunotherapy.

@en

Dramatic response of metaplastic breast cancer to chemo-immunotherapy.

@nl

type

Item

label

Dramatic response of metaplastic breast cancer to chemo-immunotherapy.

@en

Dramatic response of metaplastic breast cancer to chemo-immunotherapy.

@nl

prefLabel

Dramatic response of metaplastic breast cancer to chemo-immunotherapy.

@en

Dramatic response of metaplastic breast cancer to chemo-immunotherapy.

@nl

P1476

Dramatic response of metaplastic breast cancer to chemo-immunotherapy.

@en

P2860

Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics

Mining genome sequencing data to identify the genomic features linked to breast cancer histopathology.

Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells

Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition.

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

PD-L1 expression in triple-negative breast cancer.

Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.

Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition.

P2888

s41523-017-0011-0

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41523-017-0011-0

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sylvia Adams

P577

2017-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084130022

http://www.w3.org/2001/XMLSchema#string

P698

28649648

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5445614

http://www.w3.org/2001/XMLSchema#string

Dramatic response of metaplastic breast cancer to chemo-immunotherapy.

about

P2860

P2860

Dramatic response of metaplastic breast cancer to chemo-immunotherapy.

description

name

type

label

prefLabel

P1433

P1476

P2860

P2888

P304

P31

P356

P478

P50

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2860

P2888

P304

P31

P356

P478

P50

P577

P6179

P698

P921

P932